RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome)
Trial details
- Registry ID
- NCT07236606
- Drugs studied
- RGX-121-3102
TrialRedline tracks 3 clinical trials sponsored by REGENXBIO Inc.: 1 Phase 3, 2 Phase 2 / 3.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome)NCT07236606 | RGX-121-3102 | Active not recruiting | 2028-04-30Estimated |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)NCT05693142 | RGX-202 | Active not recruiting | 2026-09Estimated |
| CAMPSIITE™ RGX-121 Gene Therapy in Subjects With MPS II (Hunter Syndrome)NCT03566043 | RGX-121 | Active not recruiting | 2023-11-27Actual |
Names as written in the registry records.
NCT05693142 · REGENXBIO Inc.
Before: Aug 2026. After: Sep 2026.
Before: Recruiting. After: Active not recruiting.
NCT05693142 · REGENXBIO Inc.
Before: Feb 2026. After: Aug 2026.
NCT07236606 · REGENXBIO Inc.
Before: Suspended. After: Active not recruiting.
NCT07236606 · REGENXBIO Inc.
Before: Recruiting. After: Suspended.
NCT07236606 · REGENXBIO Inc.
Before: Not yet recruiting. After: Recruiting.